000			01454 a2200397 4500
005			20250517012340.0
264		0	_c20160208
008			201602s 0 0 eng d
022			_a1879-016X
024	7		_a10.1016/j.pharmthera.2015.01.003 _2doi
040			_aNLM _beng _cNLM
100	1		_aZamarin, Dmitriy
245	0	0	_aImmune checkpoint modulation: rational design of combination strategies. _h[electronic resource]
260			_bPharmacology & therapeutics _cJun 2015
300			_a23-32 p. _bdigital
500			_aPublication Type: Journal Article; Research Support, Non-U.S. Gov't; Review
650	0	4	_aAdaptive Immunity
650	0	4	_aAntibodies _xtherapeutic use
650	0	4	_aAntigen Presentation
650	0	4	_aCTLA-4 Antigen _ximmunology
650	0	4	_aCancer Vaccines _xtherapeutic use
650	0	4	_aCombined Modality Therapy
650	0	4	_aDrug Resistance, Neoplasm
650	0	4	_aHumans
650	0	4	_aImmunity, Innate
650	0	4	_aImmunologic Factors _xtherapeutic use
650	0	4	_aImmunotherapy
650	0	4	_aMolecular Targeted Therapy
650	0	4	_aNeoplasms _ximmunology
650	0	4	_aOncolytic Virotherapy
650	0	4	_aProgrammed Cell Death 1 Receptor _ximmunology
650	0	4	_aT-Lymphocytes _ximmunology
700	1		_aPostow, Michael A
773	0		_tPharmacology & therapeutics _gvol. 150 _gp. 23-32
856	4	0	_uhttps://doi.org/10.1016/j.pharmthera.2015.01.003 _zAvailable from publisher's website
999			_c24528885 _d24528885